New Delhi: COVAXIN™, India’s 1st indigenous Covid-19 vaccine, developed by Bharat Biotech successfully enters human trials.
Bharat Biotech developed India’s first indigenous vaccine COVAXIN™ against COVID19 in collaboration with ICMR and NIV. DGCI granted permission to initiate Phase I & II Human clinical trials. Human clinical trials are scheduled to start across in July 2020.
“The Drug Controller General of India – CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response,” said Bharat Biotech.
Comments are closed.